Prime Medicine has received clearance from New Zealand’s Medsafe for its clinical trial application for PM-577a, an investigational Prime Editor for Wilson’s disease. The clearance advances the gene-editing program toward clinical testing and signals progress for targeted correction of disease-causing genetic variants. PM-577a is Prime Medicine’s Prime Editing approach, which uses an engineered system to precisely write genetic changes rather than inserting a new gene. The company has been positioning the program for clinical development focused on rare, monogenic disease drivers like Wilson’s. The regulatory step in New Zealand provides an additional country foothold as Prime Medicine continues to expand the geographic and regulatory footprint for early-stage gene editing candidates.